Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for genetically defined diseases. Our current focus is on hemolytic anemias: pyruvate kinase (PK) deficiency, alpha- and beta-thalassemia and sickle cell disease. Many patients with these diseases need regular blood transfusions throughout their lives, and blood shortages brought on by the COVID-19 pandemic have created additional challenges for these communities. That’s why we want to show our support by donating blood through the American Red Cross.
The patients and families who are counting on us need extraordinary science, and they also need people with extraordinary hearts. At Agios, we have both. We’re where science meets heart.